Biocon Reports 10% Revenue Growth, Generics Turnaround; Secures U.S. Launch and Brazil Supply Deal
In the quarter ended 30 June 2026 (Q1FY27), Biocon Limited (NSE: BIOCON) posted consolidated revenue of ₹4,336 crore, up 10% year-on-year, while EBITDA margin expanded to 20.8%, per its exchange filing of 5 August 2026. The company’s investor presentation the next day described a “dramatic 355% surge” in reported net profit (to ₹141.1 crore, as per the same results filing). On the earnings call of 11 August 2026, management stated that the biosimilars segment grew 16% YoY and the generics business turned profitable, even as the services arm (Syngene) contracted.
Biosimilars up 16%, generics profitable in Q1FY27
The Q1FY27 results filing (5 August 2026) showed consolidated revenue of ₹43,360 million (₹4,336 crore) and an EBITDA margin of 20.8%. The concall transcript filed on 11 August 2026 carried management’s comments that biosimilars revenue rose 16% year-on-year and generics returned to profitability, citing product mix improvements, cost synergies and disciplined R&D. The results filing also noted that PAT was supported by other income and that diluted EPS was affected by the share issuance related to the Biocon Biologics acquisition.
Biocon Biologics becomes wholly-owned subsidiary
On 29 June 2026, Biocon completed the acquisition of the remaining 11,536,956 equity shares of Biocon Biologics Limited from 127 selling shareholders, issuing 8,786,362 new equity shares at ₹376.41 apiece, making BBL a wholly-owned subsidiary, according to the intimation filed on the same date. The preferential share swap had received shareholder approval on 7 June 2026.
Yesafili™ U.S. launch and Pertuzumab European recommendation
Biosimilars pipeline milestones accumulated during CY26. On 3 August 2026, Biocon announced the commercial launch of Yesafili™ (aflibercept-jbvf), an FDA-approved interchangeable biosimilar to Regeneron’s Eylea® 2 mg, in the United States (filing dated 3 August 2026). On 21 September 2026, the EMA’s CHMP issued a positive opinion recommending marketing authorisation for Biocon’s Pertuzumab biosimilar (Pebrilzo®) for HER2-positive breast cancer, with the European Commission to conduct a final review (filing dated 21 September 2026). Earlier, on 25 August 2026, Japanese MHLW marketing approval was obtained for the pegfilgrastim biosimilar (filing of 25 August 2026).
10-year Brazil PDP contract
On 8 September 2026, Biocon signed a partnership agreement with Bahiafarma and Bionovis for the supply of Pertuzumab under Brazil’s Productive Development Partnership (PDP) program, per the BSE filing of that date. The consortium received 100% allocation under the 10-year PDP, giving exclusive access to the country’s public healthcare market (approximately 70% of demand). Biocon will receive milestone payments and a revenue share.
Management targets H2 acceleration
On the Q1FY27 concall (11 August 2026), management said it expects H2 acceleration and a recovery at Syngene, as recorded in the transcript. No explicit quarterly revenue or profit forecasts were provided beyond that directional commentary.
Alpha Inflection is research infrastructure, not investment advice. We are not SEBI-registered investment advisers. Everything above is compiled from public corporate filings, with sources cited. Do your own research.
The filing evidence
| Date | What the filing said | Detail | Source |
|---|---|---|---|
| 5 Aug 2026 | Q1FY27 consolidated revenue was ₹43,360 million, +10.0% YoY but -4.0% QoQ, while EBITDA margin rose to 20.8% and shareholder PAT increased to ₹1,411 million; the operating recovery is improving, but PAT remains supported by other income and EPS dilution. | filing | |
| 5 Aug 2026 | Q1FY27 consolidated revenue was ₹4336 million, up 10.0% YoY, while PAT rose to ₹141.1 million and EBITDA margin expanded to 20.8%; biosimilars and generics grew but services sharply contracted and earnings quality remains mixed. | filing | |
| 6 Aug 2026 | Biocon's Q1 FY27 earnings reflect steady revenue growth of 10% YoY and a dramatic 355% surge in reported net profit, driven by biosimilars and generics, though near-term challenges persist in the services segment. | filing | |
| 11 Aug 2026 | Biocon Q1 FY27 biosimilars up 16%, generics turns profitable, Syngene decline drives mixed start; management targets H2 acceleration and Syngene recovery. | filing | |
| 10 Jun 2026 | Biocon Limited acquires equity stake in Ampin C&I Power Twelve Private Limited to enhance renewable energy consumption | Biocon Limited has acquired an equity stake in Ampin C&I Power Twelve Private Limited (AMPIN), a company engaged in the generation and supply of solar power. | filing |
| 29 Jun 2026 | Biocon completes acquisition of remaining 11.5 million shares of Biocon Biologics from 127 shareholders via a preferential share swap, making Biocon Biologics a wholly-owned subsidiary. | Biocon Limited acquired 11,536,956 equity shares of its material subsidiary Biocon Biologics Limited (BBL) from 127 selling shareholders. As consideration, Biocon issued and allotted 8,786,362 new equity shares on a preferential basis at Rs. 376.41 per share, using shareholder approval obtained on June 7, 2026. Post-transaction, BBL became a wholly-owned subsidiary of Biocon. | filing |
| 29 Jun 2026 | Biocon completes acquisition of Biocon Biologics equity from 127 shareholders via preferential share swap, making BBL a wholly-owned subsidiary. | Biocon Limited acquired 11,536,956 equity shares of its material subsidiary Biocon Biologics Limited (BBL) from 127 selling shareholders, and as consideration, issued and allotted 8,786,362 new equity shares of Biocon on a preferential basis to those sellers at Rs. 376.41 per share, resulting in BBL becoming a wholly-owned subsidiary effective June 29, 2026. | filing |
| 9 Jul 2026 | Biocon announces publication of pivotal clinical data for Yesafili™, a biosimilar to Eylea®, supporting its effectiveness in treating diabetic macular edema. | Biocon announced the publication of two clinical studies from the Phase III INSIGHT program for Yesafili™ (aflibercept-jbvf) in peer-reviewed journals, demonstrating similar safety, efficacy, and immunogenicity outcomes between patients who continued on the biosimilar and those who switched from reference aflibercept, as well as comparable efficacy across diverse patient subgroups. | filing |
| 3 Aug 2026 | Biocon launches Yesafili™, a biosimilar to Eylea®, in the U.S. for treating serious eye conditions. | Biocon announced the commercial launch of Yesafili™ (aflibercept-jbvf), an FDA-approved interchangeable biosimilar to Regeneron's Eylea® 2 mg, in the United States on August 3, 2026. | filing |
| 25 Aug 2026 | Biocon receives Japanese MHLW marketing approval for its pegfilgrastim biosimilar, strengthening its biosimilar portfolio in Japan. | Biocon Biologics, a wholly-owned subsidiary of Biocon, obtained marketing approval from Japan's Ministry of Health, Labour and Welfare for its pegfilgrastim biosimilar (biosimilar to Neulasta). Sandoz K.K. will exclusively promote, sell, and distribute the product in Japan. | filing |
| 21 Sept 2026 | Biocon's Pertuzumab biosimilar receives positive EMA CHMP opinion recommending EU marketing authorisation for HER2-positive breast cancer treatment. | Biocon announced that the EMA CHMP issued a positive opinion recommending marketing authorisation for its Pertuzumab biosimilar (Pebrilzo®) for treating HER2-positive breast cancer. The European Commission will now conduct a final review and issue a decision. | filing |
| 22 Jun 2026 | Biocon Limited informs shareholders about tax deduction at source (TDS) on the recommended final dividend for FY2025-26, pending shareholder approval. | Biocon Limited communicated to its shareholders regarding the TDS provisions applicable to the final dividend of Re. 0.50 per share recommended by the Board for FY2025-26, subject to approval at the AGM on August 6, 2026. The communication details TDS rates for resident and non-resident shareholders, required documentation to claim lower withholding rates, and the deadline of July 20, 2026 for submitting forms. | filing |
| 5 Aug 2026 | Q1FY27 operating revenue was ₹4,336 crore, up 10% YoY, and EBITDA was ₹901.7 crore, up 7%, as 17% Biopharma growth offset a 16% Services decline, but margin remained broadly flat YoY and sequentially weaker. | filing | |
| 8 Sept 2026 | Biocon secures a 10-year supply contract for Pertuzumab under Brazil's PDP program, gaining exclusive access to the country's public healthcare market. | Biocon signed a partnership agreement with Bahiafarma and Bionovis for the supply of Pertuzumab, a HER2-positive breast cancer therapy, under Brazil's Productive Development Partnership (PDP) program. The consortium received 100% allocation under the 10-year PDP, giving exclusive access to Brazil's public market (~70% of demand). Biocon will receive milestone payments and revenue share. | filing |
Quick answers
- What did Biocon disclose?
- In the quarter ended 30 June 2026 (Q1FY27), Biocon Limited (NSE: BIOCON) posted consolidated revenue of ₹4,336 crore, up 10% year-on-year, while EBITDA margin expanded to 20.8%, per its exchange filing of 5 August 2026.
- What are the key numbers?
- The Q1FY27 results filing (5 August 2026) showed consolidated revenue of ₹43,360 million (₹4,336 crore) and an EBITDA margin of 20.8%.
- What does Biocon say comes next?
- On the Q1FY27 concall (11 August 2026), management said it expects H2 acceleration and a recovery at Syngene, as recorded in the transcript. No explicit quarterly revenue or profit forecasts were provided beyond that directional commentary.
Research and educational content only. Not investment advice. Drafted from regulatory filings and published automatically — see our editorial policy.